**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65127

**Manuscript Type:** REVIEW

**Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?**

Amponsah-Dacosta E. Hepatitis B-associated HCC in Africa

Edina Amponsah-Dacosta

**Edina Amponsah-Dacosta,** Vaccines for Africa Initiative, School of Public Health and Family Medicine, University of Cape Town, Cape Town 7925, Western Cape, South Africa

**Author contributions:** Amponsah-Dacosta E defined the topic, performed the literature search, screened, and reviewed the literature, and wrote the manuscript.

**Supported by** The Harry Crossley Postdoctoral Research Fellowship 2021.

**Corresponding author: Edina Amponsah-Dacosta, PhD, Postdoctoral Fellow,** Vaccines for Africa Initiative, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, Western Cape, South Africa. edina.amponsah-dacosta@uct.ac.za

**Received:** February 28, 2021

**Revised:** May 10, 2021

**Accepted:** August 13, 2021

**Published online:**

**Abstract**

Elimination of viral hepatitis in sub-Saharan Africa by 2030 is an ambitious feat. However, as stated by the World Health Organization, there are unprecedented opportunities to act and make significant contributions to the elimination target. With 60 million people chronically infected with hepatitis B virus (HBV) of whom 38800 are at risk of developing highly fatal hepatocellular carcinoma (HCC) every year, sub-Saharan Africa faces one of the greatest battles towards elimination of viral hepatitis. There is a need to examine progress in controlling the disproportionate burden of HBV-associated HCC in sub-Saharan Africa within the context of this elimination target. By scaling-up coverage of hepatitis B birth dose and early childhood vaccination, we can significantly reduce new cases of HCC by as much as 50% within the next three to five decades. Given the substantial reservoir of chronic HBV carriers however, projections show that HCC incidence and mortality rates in sub-Saharan Africa will double by 2040. This warrants urgent public health attention. The trends in the burden of HCC over the next two decades, will be determined to a large extent by progress in achieving early diagnosis and appropriate linkage to care for high-risk chronic HBV infected persons.

**Key Words:** Hepatitis B virus; Viral hepatitis, Hepatocellular Carcinoma; Elimination; Human Immunodeficiency Virus; Sub-Saharan Africa

Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? *World J Gastroenterol* 2021; In press

**Core Tip:** Chronic hepatitis B virus (HBV) infection is the primary risk factor for hepatocellular carcinoma (HCC) in sub-Saharan Africa. In 2020, HBV-associated HCC accounted for approximately 36700 deaths. By 2040, it is projected that approximately 72200 people will die each year from this disease without an intensive public health response. The high mortality-to-incidence ratio associated with HCC in sub-Saharan Africa suggests significant inequities in access to appropriate health care. This review examines the evidence on the extent of the disease burden in sub-Saharan Africa and advocates for prioritizing HCC control as part of ongoing viral hepatitis elimination strategies within this region.

**INTRODUCTION**

Despite the availability of a safe and effective prophylactic vaccine since 1982, chronic hepatitis B which is a serious liver disease caused by hepatitis B virus (HBV), remains a major global public health threat. Estimates from the World Health Organization’s (WHO) current Global Hepatitis Report suggest that in 2015, 3.5% (257 million persons) of the world’s population were living with chronic hepatitis B, with the Western Pacific and sub-Saharan African regions bearing the brunt (68%) of the disease burden (WHO, 2017). In addition to this, 887000 deaths due to HBV-associated hepatic sequelae such as acute hepatitis, liver cirrhosis and liver cancer or hepatocellular carcinoma (HCC), were recorded worldwide[1].

With an estimated 830180 associated deaths recorded in 2020, liver cancer remains a leading cause of cancer-related death worldwide, third only to lung (1.8 million deaths) and colorectal (935153 deaths) cancers[2]. Globally, incidence rates of liver cancer have remained high, with 905677 newly diagnosed cases in 2020 [compared to 748000 (5.9% of all cancers) new cases in 2008, for example[3]], representing 4.7% of all cancer cases recorded in that year alone[2]. The most common type of malignant transformation in the liver is HCC (75%-85%), followed by intrahepatic cholangiocarcinoma (10%-15%), with other rare types accounting for the remainder of all primary liver cancers. The geographic distribution of the incidence of HCC tends to mirror that of its major risk factors, chronic hepatitis B and hepatitis C virus (HCV) infection, which account for approximately 56% and 20% of all HCC cases, respectively[2,4-6]. This implies that the highest incidence rates [age-standardized incidence rate (ASIR) > 20 cases per 100000 persons per year] of HCC are recorded in hepatitis B endemic countries including those in sub-Saharan Africa, while non-endemic regions like Europe and North America report relatively lower incidence rates (ASIR < 10 cases per 100000 persons per year)[2,7-9]. A further cause for concern in most resource limited countries within regions like sub-Saharan Africa where HCC screening and diagnostic services, and medical interventions are often inadequate, is the poor survival and extremely high mortality rates associated with HCC. Approximately 93% of patients die within a year of the onset of symptoms[7,9-11]. Evidently, elimination of viral hepatitis caused by HBV and HCV presents the best opportunity to reduce the incidence of HCC, especially in regions like sub-Saharan Africa, where the disease burden and need for intervention are oftentimes the greatest.

Recognizing the devastating impact of viral hepatitis on global health, the WHO in May 2016 adopted a Global Health Sector Strategy on Viral Hepatitis aimed at achieving a 90% reduction in new cases and a 65% reduction in mortality due to HBV and HCV infection, towards an ambitious target of eliminating viral hepatitis by 2030[12]. To eliminate chronic hepatitis B, the health service targets to be attained by 2030 include; 90% coverage of routine childhood hepatitis B vaccination, a reduction in mother-to-child transmission (MTCT) of HBV such as through > 90% coverage of hepatitis B birth dose vaccination, 100% of all blood donations screened for HBV, 90% of all HBV infections diagnosed, and 80% of eligible persons with chronic hepatitis B linked to appropriate treatment and care[12]. While largely in the planning phase of executing this global strategy, a recent WHO report suggests that overall, member states are making progress in developing national viral hepatitis management guidelines and strategic plans towards attaining the elimination targets, although availability of dedicated funding to support implementation appears to be an important challenge in some countries[13].

To contribute to the knowledgebase on the scope of the burden of chronic hepatitis B in sub-Saharan Africa, the status and public health response to HBV-associated HCC in sub-Saharan Africa are reviewed. Opportunities and challenges towards achieving the 2030 viral hepatitis elimination target – at least where chronic hepatitis B and HCC are concerned – are also identified, with the intent of arguing for continued financial and technical investments to support ongoing health sector strategies and interventions within sub-Saharan Africa.

**Global burden of chronic hepatitis B**

The seroprevalence of chronic hepatitis B which is based on the detection of the hepatitis B surface antigen (HBsAg) within the general population, is highly variable worldwide. This variability is demonstrated by substantial regional and inter-country disparities in the burden of the disease. Available estimates[14] suggest that HBsAg prevalence rates in the Americas, for example, range from < 2% in countries like the United States of America, Mexico, and Guatemala, to 13.55% (95%CI: 9.00-19.89) in Haiti. In the South East Asian region, HBsAg prevalence rates range from 0.82% (95%CI: 0.80–0.84) in Nepal to as high as 6.42% (95%CI: 6.37–6.47) in Thailand. Overall, countries within the Eastern Mediterranean and European regions mostly have lower-intermediate endemicity levels (HBsAg prevalence ranging from 2% to 4.99%) while the Western Pacific can be classified as a high-intermediate endemic region with most countries recording HBsAg prevalence rates >5%. Within the African region, the lowest HBsAg prevalence rates are reported in countries like Seychelles [0.48% (95%CI: 0.12-1.90)], Eritrea [2.49% (95%CI: 2.32-2.67)], and Algeria [2.89% (95%CI: 2.50-3.33)], while Mauritania [16.16% (95%CI: 14.92-17.49)], Liberia [17.55% (95%CI: 15.70-19.55)], Swaziland [19% (95%CI: 17.65-20.43)], and South Sudan [22.38% (95%CI: 20.10-24.83)] have recorded some of the highest prevalence estimates[14].

**Epidemiological shift in the burden of chronic hepatitis B in sub-Saharan Africa**

Historically, sub-Saharan Africa has been classified as hyper-endemic for chronic hepatitis B based on the detection of HBsAg among ≥ 8% of the general population. Table 1 shows the variable prevalence of HBsAg among populations in some sub-Saharan African countries prior to introduction of universal hepatitis B vaccination and how this has changed over time post-vaccine introduction[15-47]. At the peak of the hepatitis B epidemic in sub-Saharan Africa, the disease burden was characterized by a preponderance of horizontal transmission of HBV among young children (between 1-4 years of age), 30%-50% of whom would go on to develop chronic hepatitis B, and later progress to potentially fatal sequelae (mainly liver cirrhosis and HCC) within 30-50 years after infection[15,29,48]. This contrasts with HBV infection acquired during adulthood which carries a considerably lower risk (< 5%) of progression to chronic disease as observed in non-endemic regions of the world.

Currently, the prevalence of HBsAg in sub-Saharan Africa is reported to be 6.1%, equating to 60 million people living with chronic hepatitis B, of which approximately 4.8 million are children < 5 years of age[1]. The decline in the prevalence of HBsAg within the population can be largely attributed to the success of universal childhood hepatitis B vaccination programmes implemented in sub-Saharan Africa since the early 1990s[49]. In most sub-Saharan African countries, the first dose of the hepatitis B vaccine is administered at 6 weeks of age, with the remainder of the regimen completed within the 1st year of life in an effort to interrupt transmission and prevent incident HBV infection in early childhood. Coverage of the third dose of the hepatitis B vaccine in the region is currently estimated at 73%[50]. Countries like The Gambia and South Africa with longstanding hepatitis B vaccination programmes have achieved marked declines in incident infections over time, especially among children < 5 years of age (Table 1).

Despite this success, we are still decades away from realizing the full benefits of universal childhood hepatitis B vaccination programmes in sub-Saharan Africa, given the protracted natural history of chronic hepatitis B, and the long interval between early childhood infection and development of chronic sequelae[51,52]. As such, high prevalence rates of HBsAg persist among a reservoir of adult populations, including women of childbearing age, most of whom were born before the introduction of the hepatitis B vaccine or were not fully vaccinated in infancy (Table 1). This continues to feed the epidemic in sub-Saharan Africa, contributing to the 87890 HBV-associated deaths (approximately 10% of the global total) recorded each year[1]. What further compounds the situation in sub-Saharan Africa is the disproportionate burden of human immunodeficiency virus (HIV) co-infection (69% of all HBV-HIV co-infected persons reside in sub-Saharan Africa) which is associated with a more severe prognosis than that observed in HBV mono-infected individuals[53-55]. Emerging evidence also suggests that perinatal transmission or MTCT of HBV, which was previously presumed to be insignificant in the epidemiology of chronic hepatitis B in sub-Saharan Africa, actually contributes to 367250 incident HBV infections (twice the number of paediatric HIV infections) among neonates annually[56]. In fact, the risk of HBV MTCT increases by up to 2.5-fold among the substantial population of HBV-HIV co-infected pregnant women in sub-Saharan Africa, compared to their HBV mono-infected counterparts[57-60]. This is concerning, given that perinatally acquired HBV infections carry a 90% risk of progression to chronic hepatitis B. This implies that hepatitis B vaccination from 6 weeks of age may be inadequate in preventing incident HBV infections among neonates, especially where the burden of maternal HBV-HIV co-infection is high and prevention of HBV MTCT (PMTCT) strategies are sub-optimal, as is the case in most sub-Saharan African countries. This is a stark contrast to HIV MTCT in sub-Saharan Africa which is on course for elimination due to rapid expansion of antenatal screening and access to timely HIV antiretroviral therapy[61]. The marked decline in HIV MTCT has led to a growing population of HIV-exposed uninfected children in sub-Saharan Africa. Of the 14.8 million HIV-exposed uninfected children in the world, 90% live in sub-Saharan Africa[62]. Although inconclusive, there is some evidence to suggest that HIV-exposed uninfected children may have a modified immune response to hepatitis B vaccination and may also be at increased risk for HBV infection, presenting an additional complexity to elimination strategies in sub-Saharan Africa[58,63-66].

**Epidemiological trends in HBV-associated HCC in sub-Saharan Africa**

Of the 60 million people currently living with chronic hepatitis B in sub-Saharan Africa, 38800 are at risk of developing HCC every year, characterized by an aggressive clinical course[2,67,68]. In addition, approximately 93% (36700) of persons with HCC will die within a year of their diagnosis without appropriate and timely medical intervention[2,11,67]. Most of these HCC cases (and deaths) will occur among a predominantly male population (sex ratio of 2:1) with age at diagnosis ranging between 38-67 years (compared to 50-70 years in resource rich countries), who are in their prime reproductive and working years, draining productive capacity, and placing a further burden on already strained economic, societal, and health, systems in sub-Saharan Africa[9,11,69-71]. While cases of paediatric HCC are diagnosed more frequently in some sub-Saharan African countries than those in Europe and North America for example, they remain uncommon when compared to the HCC incidence among adult populations[72-75]. Within the next two decades, HCC incidence and mortality rates in sub-Saharan Africa are predicted to double (Figure 1[67,76,77]) unless addressed through reforms in regional and national health policy and practice, including intensifying prevention, diagnostic and treatment strategies, in a whole system approach.

A comparison of the 2020 estimates of age-standardized liver cancer (mainly HCC) incidence and mortality (ASMR) rates in sub-Saharan Africa *vs* other regions of the world is shown in Figure 2[2,67,78]. With ASIRs of 8.1 and 4.2, and ASMRs of 7.8 and 4.0 per 100000 persons per year among men and women, respectively, HCC is a common cause of cancer-related morbidity and mortality in sub-Saharan Africa. There are substantial regional variations in HCC incidence and mortality rates across sub-Saharan Africa. Among males for example, the highest HCC ASIRs (> 12.9 per 100000 persons per year) and ASMRs (> 12.6 per 100000 persons per year) are recorded in West African countries, while East African countries generally appear to experience a lower burden (ASIRs < 5.1 and ASMRs < 4.9 per 100000 persons per year) of the disease (Figures 3 and 4)[2,67,78]. It should be noted however, that the true burden of HCC in sub-Saharan Africa is grossly underestimated by as much as 40%, given that cases are often underreported due to challenges in effectively diagnosing the disease, while the quality and coverage of data in population-based cancer registries are suboptimal[9,11,79].

The overall HCC mortality-to-incidence ratio (MIR = 0.95) in sub-Saharan Africa is comparable to that in the Western Pacific and South-East Asian regions (MIR = 0.95) but higher than that in Northern America (MIR = 0.82)[80]. This high MIR reflects disparities in outcomes of HCC in sub-Saharan Africa compared to resource-rich regions, owing to limited availability and accessibility of diagnostic and treatment services[81,82]. These disparities go beyond the clinical context and are rooted in socio-economic inequities. A recent South African study[82] investigating trends in liver cancer-associated mortality found key socio-economic and sex disparities. The average MIR for black South African men and women was 4.0 and 3.3 respectively, compared to 2.2 and 1.8 among their white counterparts. This underscores the inequities in HCC prognosis experienced by socio-economically disadvantaged populations[82]. Evidently, addressing the disproportionate burden of HCC in sub-Saharan Africa will require careful consideration of socio-economic and demographic inequities prevalent within its population.

**Predominance of HBV-associated hepatocarcinogenesis in sub-Saharan Africa**

The association of chronic hepatitis B with the development of most cases of HCC [attributable fraction, AF = 50% (95%CI: 39-60)] occurring among sub-Saharan African populations is well established in the literature[5,6,83,84]. The remainder of HCC cases are typically associated with HCV infection [AF = 21% (95%CI: 13-32)] and exposure to the dietary carcinogen, aflatoxin B1, although metabolic syndrome is emerging as an important risk factor in sub-Saharan Africa[6,85-88]. In comparison, the major risk factors for HCC development in low incidence regions of the world (North America, and Western, Central, and Eastern Europe) include host and environmental factors such as genetic predisposition to primary liver cancer, chronic alcohol intake, obesity, hemochromatosis, and exposure to nitrosamines, followed by HCV infection[71,89-91]. It is worth noting however, that the potential for interaction among these different risk factors, leading to synergistic or additive effects in the development of HCC in both endemic and non-endemic regions of the world cannot be undervalued.

The mechanism underlying HBV-associated hepatocarcinogenesis is multifactorial, involving various direct and indirect viral mechanisms required to stimulate the host oncogenic pathway and achieve hepatocyte transformation[92,93]. These mechanisms, which may act synergistically, include integration of the viral DNA into host genome, persistent and enhanced HBV replication, as well as infection with specific HBV genotypes and HBV genetic variants. Important HBV-specific risk factors involved in the development of HCC have been identified in previous studies conducted in sub-Saharan Africa. In a recent case control study, Atsama Amougou *et al*[94] demonstrated the role of circulating quasi-genotypes and viral genetic variations in HBV-associated hepatocarcinogenesis among Cameroonian HCC patients. A previous study[95] conducted in South Africa found an increasing risk of HCC with increasing HBV viremia, showing an increasing trend in odds ratio (OR) from ≥ 2000 IU/mL (OR = 8.55, 95%CI: 3.00 ± 24.54) to ≥ 200000 IU/mL (OR 16.93, 95%CI: 8.65 ± 33.13). While this finding is consistent with that from another study conducted in The Gambia, there is evidence to suggest that low-level viremia may also be a significant risk factor for HCC[96]. The South African study further demonstrated a 4-fold increase in the risk of developing HCC among participants with occult HBV infection (HBsAg negative but HBV DNA positive infections) compared to controls[95]. Interestingly, a previous longitudinal study conducted in The Gambia which followed chronic carriers of HBV over a median duration of 28.4 years (interquartile rage = 17.7-32.7) found that maternal HBsAg positivity – as a proxy of MTCT of HBV – was statistically significantly (*P* < 0.001) associated with a higher incidence of HCC [crude incidence rates of 89.2 (95%CI: 22.3–356.8) *vs* 0 (unadjusted) per 100 000 persons per year, among those born to HBsAg positive *vs* HBsAg negative mothers][70]. Based on these findings, the authors recommend further investigation into the feasibility of scaling-up implementation of hepatitis B birth dose vaccination and other PMTCT strategies within sub-Saharan Africa in order to interrupt incident HBV infections among neonates[70]. Of the 111 countries which report having introduced a hepatitis B birth dose as part of national routine immunization programmes, only 11 (Algeria, Botswana, Cabo Verde, Côte d'Ivoire, The Gambia, Mauritania, Namibia, Nigeria, Sao Tome and Principe, Senegal, and Zambia) are in Africa[50]. While the global coverage of the birth dose is reported to be suboptimal (43%), that in the sub-Saharan African region is even more dismal at an estimated 6%[50]. When considered together with the reported low coverage of maternal screening for HBV infection and linkage to antiviral prophylaxis, current PMTCT strategies are inadequate to significantly reduce perinatal transmission and avert neonatal HBV infections within the region[97,98].

**Challenges affecting management of HBV-associated HCC in sub-Saharan Africa**

Management of chronic hepatitis B involves suppressing HBV viremia and minimizing the risk of progression to liver cirrhosis, chronic liver failure and HCC, using oral nucleotide/nucleoside analogues like tenofovir disoproxil fumarate (TDF) and entecavir. Treatment with nucleotide/nucleoside analogues is indicated in chronic carriers with elevated HBV viremia, elevated liver enzymes, and evidence of liver fibrosis and cirrhosis. Appropriate linkage to care requires the identification of chronically infected individuals who are eligible for treatment through HBV screening programmes[99]. It is estimated that < 1% of chronic HBV infected individuals in sub-Saharan Africa are currently being diagnosed[100]. In addition, there are major gaps in determining treatment eligibility. Significant limitations have been identified when applying internationally recommended treatment eligibility criteria in the sub-Saharan African context. Only 10%–15% of persons with liver cirrhosis are detected for linkage to appropriate treatment[99-102].

Low uptake of HBV screening and treatment services in sub-Saharan Africa has been attributed to the lack of publicly funded, national HBV screening and treatment programmes. This leaves the responsibility for seeking an HBV test to the patient, which is highly detrimental when considered in the context of limited public awareness of the virus, and the asymptomatic nature of the infection until onset of late-stage sequelae[103]. As currently available nucleotide/nucleoside analogues cannot eradicate intrahepatic HBV DNA, treatment is typically lifelong, and this amounts to a significant cost[100,102]. A recent WHO report indicates that by 2019, < 8 of the 47 member states within the WHO African region (WHO AFRO) had established subsidized HBV treatment programmes[16]. This suggests that a substantial proportion of chronic HBV carriers continue to incur undue financial burden as a consequence of paying out-of-pocket for the treatment they need, while others may be unable to afford it altogether. In Ghana, the annual cost of TDF is estimated at $670 which, when considered against an average annual income of $1778, is a major constraint to accessing lifesaving treatment[104]. It should not come as a surprise then that most patients in sub-Saharan Africa present to health care facilities with established liver cirrhosis or symptomatic advanced-stage HCC, at which point the prognosis is grim and therapeutic options are limited to palliative care.

**Towards elimination of chronic hepatitis B and control of HCC in sub-Saharan Africa**

Future trends in the burden of HCC in sub-Saharan Africa will be determined by our progress in preventing new HBV infections, screening and treating existing chronic hepatitis B cases, as well as detecting and appropriately managing HCC. As part of a scorecard to monitor progress towards elimination of viral hepatitis within WHO AFRO in 2019, six core indicators were listed; (1) development of national hepatitis policies in the form of a national strategic plan for viral hepatitis; (2) implementation of hepatitis B birth dose vaccination; (3) achieving > 90% national coverage of the third dose of the hepatitis B vaccine; (4) being on track for the HBV and HCV 2020 testing target; (5) implementation of a national hepatitis treatment programme; and (6) commemoration of World Hepatitis Day in 2018. Overall, most sub-Saharan African countries were found lagging in almost all indicators[16].

Within the next decade, there is a need to scale-up primary prevention of incident HBV infections in sub-Saharan Africa. Despite adopting resolutions to improve hepatitis B birth dose and routine childhood vaccination in WHO AFRO by 2020, implementation and coverage of the birth dose remains unacceptably low, while coverage of routine childhood vaccination remains well below the global average of 84%[49,105,106]. Recognizing the significant threat of HBV MTCT to public health in sub-Saharan Africa, there have been renewed calls to expand access to the hepatitis B birth dose and leverage HIV PMTCT infrastructure in screening pregnant women and providing timely prophylaxis[56,98,107]. The future research agenda in sub-Saharan Africa should include investigating the need for tailored hepatitis B vaccination strategies for unique populations like HIV-exposed uninfected children.

As national governments grapple with the feasibility of implementing subsidized hepatitis surveillance and treatment programmes, the success of the HIV test and treat model in sub-Saharan Africa has been recognized as an opportunity to expand screening and antiviral treatment for chronic hepatitis B in the interim. To ensure a comprehensive package of care, there is a need to prioritize integration of cost-effective point-of-care screening tests with good diagnostic accuracy, guided by appropriate treatment eligibility criteria[49,108].

Within the past decade, there have been significant advances in the development of new diagnostic and therapeutic approaches for HCC, with prospects for further innovation in the field[109,110]. These advances present unique opportunities to improve surveillance and management of HCC. Biannual surveillance among high-risk chronic carriers of HBV using both liver ultrasonography and serum α-fetoprotein concentrations, is commonly used for early detection of progression to HCC. Curative treatment approaches for early-stage HCC include surgical resection, tumour ablation, or liver transplantation. For advanced-stage HCC, combination treatment using atezolizumab and bevacizumab over sorafenib alone, have shown promising long-term outcomes in phase III clinical trials[110]. Other immunotherapeutic agents for the treatment of late-stage HCC have also been recently explored[109]. While all these advancements present much needed opportunities to improve the quality of life of patients with HCC, the cost and feasibility of implementation within the sub-Saharan African public health context are always important considerations.

**CONCLUSION**

Ultimately, sub-Saharan Africa faces one of the toughest battles against chronic hepatitis B and HCC. Despite this, there are opportunities to achieve significant reductions in incident HBV infections and alter future trends in the burden of HCC. This calls for strong political will, regional coordination, and effective partnerships with donor agencies and non-governmental organizations in order to mobilize financial investments and technical support. Finally, the role of advocacy and awareness campaigns like World Hepatitis Day in enabling public ownership and demand for accessible, equitable, and quality health services cannot be undervalued.

**REFERENCES**

1 **World Health Organization.** Global hepatitis report, 2017. Geneva: World Health Organization, 2017

2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

3 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

4 **Herbst DA**, Reddy KR. Risk factors for hepatocellular carcinoma. *Clin Liver Dis (Hoboken)* 2012; **1**: 180-182 [PMID: 31186882 DOI: 10.1002/cld.111]

5 **de Martel C**, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. *Hepatology* 2015; **62**: 1190-1200 [PMID: 26146815 DOI: 10.1002/hep.27969]

6 **Maucort-Boulch D**, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. *Int J Cancer* 2018; **142**: 2471-2477 [PMID: 29388206 DOI: 10.1002/ijc.31280]

7 **Ozakyol A**. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). *J Gastrointest Cancer* 2017; **48**: 238-240 [PMID: 28626852 DOI: 10.1007/s12029-017-9959-0]

8 **Tang A**, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. *Abdom Radiol (NY)* 2018; **43**: 13-25 [PMID: 28647765 DOI: 10.1007/s00261-017-1209-1]

9 **Zakharia K**, Luther CA, Alsabbak H, Roberts LR. Hepatocellular carcinoma: Epidemiology, pathogenesis and surveillance - implications for sub-Saharan Africa. *S Afr Med J* 2018; **108**: 35-40 [PMID: 30182911 DOI: 10.7196/SAMJ.2018.v108i8b.13499]

10 **Kew MC**. Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. *World J Hepatol* 2012; **4**: 99-104 [PMID: 22489262 DOI: 10.4254/wjh.v4.i3.99]

11 **Kew MC**. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. *Ann Hepatol* 2013; **12**: 173-182 [PMID: 23396727]

12 **World Health Organization.** Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geneva: World Health Organization, 2016

13 **Smith S**, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, Rewari B, Mozalevskis A, Shibeshi M, Mumba M, Le LV, Ishikawa N, Nolna D, Sereno L, Gore C, Goldberg DJ, Hutchinson S. Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. *JHEP Rep* 2019; **1**: 81-89 [PMID: 32039355 DOI: 10.1016/j.jhepr.2019.04.002]

14 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]

15 **Kiire CF**. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. *Gut* 1996; **38 Suppl 2**: S5-12 [PMID: 8786055 DOI: 10.1136/gut.38.suppl\_2.s5]

16 **World Health Organization Regional Office for Africa**. Hepatitis scorecard for the WHO Africa Region implementing the hepatitis elimination strategy. 2019. Available from: https://www.afro.who.int/publications/hepatitis-scorecard-who-africa-region-implementing-hepatitis-elimination-strategy

17 **Kwizera R**, Moibéni A, Shenawy F, Youssif M. The prevalence of hepatitis B and C among blood donors at the National Blood Transfusion Center (CNTS) in Burundi. *Pan Afr Med J* 2018; **31**: 119 [PMID: 31037179 DOI: 10.11604/pamj.2018.31.119.14571]

18 **Werner GT**, Frösner GG, Fresenius K. Prevalence of serological hepatitis A and B markers in a rural area of northern Zaire. *Am J Trop Med Hyg* 1985; **34**: 620-624 [PMID: 2988353 DOI: 10.4269/ajtmh.1985.34.620]

19 **Thompson P**, Parr JB, Holzmayer V, Carrel M, Tshefu A, Mwandagalirwa K, Muwonga J, Welo PO, Fwamba F, Kuhns M, Jhaveri R, Meshnick SR, Cloherty G. Seroepidemiology of Hepatitis B in the Democratic Republic of the Congo. *Am J Trop Med Hyg* 2019; **101**: 226-229 [PMID: 31074406 DOI: 10.4269/ajtmh.18-0883]

20 **Tsega E**, Mengesha B, Nordenfelt E, Hansson BG, Lindberg J. Prevalence of hepatitis B virus markers among Ethiopian blood donors: is HBsAg screening necessary? *Trop Geogr Med* 1987; **39**: 336-340 [PMID: 3451408]

21 **Argaw B**, Mihret A, Aseffa A, Tarekegne A, Hussen S, Wachamo D, Shimelis T, Howe R. Sero-prevalence of hepatitis B virus markers and associated factors among children in Hawassa City, southern Ethiopia. *BMC Infect Dis* 2020; **20**: 528 [PMID: 32698884 DOI: 10.1186/s12879-020-05229-7]

22 **Belyhun Y**, Maier M, Mulu A, Diro E, Liebert UG. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. *BMC Infect Dis* 2016; **16**: 761 [PMID: 27993129 DOI: 10.1186/s12879-016-2090-1]

23 **Fortuin M**, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, Inskip HM, George MO, Whittle HC. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. *Lancet* 1993; **341**: 1129-1131 [PMID: 8097813 DOI: 10.1016/0140-6736(93)93137-p]

24 **Peto TJ**, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. *BMC Infect Dis* 2014; **14**: 7 [PMID: 24397793 DOI: 10.1186/1471-2334-14-7]

25 **Bittaye M**, Idoko P, Ekele BA, Obed SA, Nyan O. Hepatitis B virus sero-prevalence amongst pregnant women in the Gambia. *BMC Infect Dis* 2019; **19**: 259 [PMID: 30876397 DOI: 10.1186/s12879-019-3883-9]

26 **Hyams KC**, Okoth FA, Tukei PM, Mugambi M, Johnson B, Morrill JC, Gray GC, Woody JN. Epidemiology of hepatitis B in eastern Kenya. *J Med Virol* 1989; **28**: 106-109 [PMID: 2786919 DOI: 10.1002/jmv.1890280210]

27 **Awili HO**, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B Virus Infection in Adolescent Blood Donors within Selected Counties of Western Kenya. *Biomed Res Int* 2020; **2020**: 8578172 [PMID: 32685533 DOI: 10.1155/2020/8578172]

28 **Maupas P**, Chiron JP, Goudeau A, Coursaget P, Perrin J, Barin F, Yvonnet B, Dubois F, Duflo B, Duflo-Moreau B, Sidibe S, Diallo AN. [Epidemiology and pathologic results of chronic carriers state of hepatitis B in Mali]. *Bull Soc Pathol Exot Filiales* 1981; **74**: 722-732 [PMID: 7343138]

29 **Kiire CF**. Hepatitis B infection in sub-Saharan Africa. The African Regional Study Group. *Vaccine* 1990; **8 Suppl**: S107-12; discussion S134-8 [PMID: 2139278 DOI: 10.1016/0264-410x(90)90229-f]

30 **Mabunda N**, Zicai AF, Ismael N, Vubil A, Mello F, Blackard JT, Lago B, Duarte V, Moraes M, Lewis L, Jani I. Molecular and serological characterization of occult hepatitis B among blood donors in Maputo, Mozambique. *Mem Inst Oswaldo Cruz* 2020; **115**: e200006 [PMID: 32997000 DOI: 10.1590/0074-02760200006]

31 **Botha JF**, Ritchie MJ, Dusheiko GM, Mouton HW, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. *Lancet* 1984; **1**: 1210-1212 [PMID: 6144925 DOI: 10.1016/s0140-6736(84)91694-5]

32 **Mhata P**, Rennie TW, Small LF, Nyarang'o PM, Chagla Z, Hunter CJ. Distribution of hepatitis B virus infection in Namibia. *S Afr Med J* 2017; **107**: 882-886 [PMID: 29022533 DOI: 10.7196/SAMJ.2017.v107i10.12171]

33 **Mavenyengwa RT**, Mukesi M, Chipare I, Shoombe E. Prevalence of human immunodeficiency virus, syphilis, hepatitis B and C in blood donations in Namibia. *BMC Public Health* 2014; **14**: 424 [PMID: 24884633 DOI: 10.1186/1471-2458-14-424]

34 **Nasidi A**, Harry TO, Vyazov SO, Munube GM, Azzan BB, Ananiev VA. Prevalence of hepatitis B infection markers in representative areas of Nigeria. *Int J Epidemiol* 1986; **15**: 274-276 [PMID: 3721692 DOI: 10.1093/ije/15.2.274]

35 **Ezeilo MC**, Engwa GA, Iroha RI, Odimegwu DC. Seroprevalence and Associated Risk Factors of Hepatitis B Virus Infection Among Children in Enugu Metropolis. *Virology (Auckl)* 2018; **9**: 1178122X18792859 [PMID: 30150873 DOI: 10.1177/1178122X18792859]

36 **Federal Ministry of Health,** **Nigeria**. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018: Technical Report. Abuja, Nigeria; 2019. Available from: https://www.naiis.ng/resource/NAIIS-Report-2018.pdf

37 **Twagirumugabe T**, Swaibu G, Walker TD, Lindh M, Gahutu JB, Bergström T, Norder H. Hepatitis B virus strains from Rwandan blood donors are genetically similar and form one clade within subgenotype A1. *BMC Infect Dis* 2017; **17**: 32 [PMID: 28056881 DOI: 10.1186/s12879-016-2149-z]

38 **Makuza JD**, Nisingizwe MP, Rwema JOT, Dushimiyimana D, Habimana DS, Umuraza S, Serumondo J, Ngwije A, Semakula M, Gupta N, Nsanzimana S, Janjua NZ. Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study. *BMJ Open* 2020; **10**: e036711 [PMID: 32660951 DOI: 10.1136/bmjopen-2019-036711]

39 **Barin F**, Perrin J, Chotard J, Denis F, N'Doye R, Diop Mar I, Chiron JP, Coursaget P, Goudeau A, Maupas P. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. *Prog Med Virol* 1981; **27**: 148-162 [PMID: 6972051]

40 **Lô G**, Sow-Sall A, Diop-Ndiaye H, Babacar N, Diouf NN, Daffé SM, Ndao B, Thiam M, Mbow M, Soumboundou MB, Lemoine M, Sylla-Niang M, Ndiaye O, Boye CS, Mboup S, Touré-Kane NC. Hepatitis B virus (HBV) infection amongst children in Senegal: current prevalence and seroprotection level. *Pan Afr Med J* 2019; **32**: 140 [PMID: 31303913 DOI: 10.11604/pamj.2019.32.140.14485]

41 **Coste M**, De Sèze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). *BMJ Open* 2019; **9**: e030211 [PMID: 31320358 DOI: 10.1136/bmjopen-2019-030211]

42 **Prabdial-Sing N**, Makhathini L, Smit SB, Manamela MJ, Motaze NV, Cohen C, Suchard MS. Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance. *PLoS One* 2019; **14**: e0217415 [PMID: 31150445 DOI: 10.1371/journal.pone.0217415]

43 **Samsunder N**, Ngcapu S, Lewis L, Baxter C, Cawood C, Khanyile D, Kharsany ABM. Seroprevalence of hepatitis B virus: Findings from a population-based household survey in KwaZulu-Natal, South Africa. *Int J Infect Dis* 2019; **85**: 150-157 [PMID: 31202910 DOI: 10.1016/j.ijid.2019.06.005]

44 **Bwogi J**, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, Opio A, Downing R, Biryahwaho B, Lewis RF. Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. *Afr Health Sci* 2009; **9**: 98-108 [PMID: 19652743]

45 **Ministry of Health,** **Uganda**. Uganda Population-based HIV Impact Assessment (UPHIA) 2016–2017: Final Report: Kampala, Ministry of Health; 2019. Available from: https://phia.icap.columbia.edu/wp-content/uploads/2019/07/UPHIA\_Final\_Report\_Revise\_07.11.2019\_Final\_for-web.pdf

46 **Tswana S**, Chetsanga C, Nyström L, Moyo S, Nzara M, Chieza L. A sero-epidemiological cross-sectional study of hepatitis B virus in Zimbabwe. *S Afr Med J* 1996; **86**: 72-75 [PMID: 8685787]

47 **Mavenyengwa RT**, Moyo SR, Nordbø SA. Streptococcus agalactiae colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from Zimbabwe. *Eur J Obstet Gynecol Reprod Biol* 2010; **150**: 34-38 [PMID: 20189288 DOI: 10.1016/j.ejogrb.2010.02.021]

48 **Kew MC**. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. *Pathol Biol (Paris)* 2010; **58**: 273-277 [PMID: 20378277 DOI: 10.1016/j.patbio.2010.01.005]

49 **Spearman CW**, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. *Lancet Gastroenterol Hepatol* 2017; **2**: 900-909 [PMID: 29132759 DOI: 10.1016/S2468-1253(17)30295-9]

50 **World Health Organization**. World Health Organization/UNICEF joint reporting process. Geneva: World Health Organization/UNICEF, 2020

51 **Hadziyannis SJ**. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. *J Hepatol* 2011; **55**: 183-191 [PMID: 21238520 DOI: 10.1016/j.jhep.2010.12.030]

52 **Croagh CM**, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. *World J Gastroenterol* 2014; **20**: 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395]

53 **Kew MC**. Hepatitis B virus / human immunodeficiency virus co-infection and its hepatocarcinogenic potential in sub-saharan black africans. *Hepat Mon* 2012; **12**: e7876 [PMID: 23166538 DOI: 10.5812/hepatmon.7876]

54 **Matthews PC**, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. *J Clin Virol* 2014; **61**: 20-33 [PMID: 24973812 DOI: 10.1016/j.jcv.2014.05.018]

55 **Platt L**, French CE, McGowan CR, Sabin K, Gower E, Trickey A, McDonald B, Ong J, Stone J, Easterbrook P, Vickerman P. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. *J Viral Hepat* 2020; **27**: 294-315 [PMID: 31603999 DOI: 10.1111/jvh.13217]

56 **Keane E**, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment Pharmacol Ther* 2016; **44**: 1005-1017 [PMID: 27630001 DOI: 10.1111/apt.13795]

57 **Andersson MI**, Maponga TG, Ijaz S, Barnes J, Theron GB, Meredith SA, Preiser W, Tedder RS. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. *Vaccine* 2013; **31**: 5579-5584 [PMID: 23973500 DOI: 10.1016/j.vaccine.2013.08.028]

58 **Chasela CS**, Kourtis AP, Wall P, Drobeniuc J, King CC, Thai H, Teshale EH, Hosseinipour M, Ellington S, Codd MB, Jamieson DJ, Knight R, Fitzpatrick P, Kamili S, Hoffman I, Kayira D, Mumba N, Kamwendo DD, Martinson F, Powderly W, Teo CG, van der Horst C; BAN Study Team. Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. *J Hepatol* 2014; **60**: 508-514 [PMID: 24211737 DOI: 10.1016/j.jhep.2013.10.029]

59 **Thumbiran NV**, Moodley D, Parboosing R, Moodley P. Hepatitis B and HIV co-infection in pregnant women: indication for routine antenatal hepatitis B virus screening in a high HIV prevalence setting. *S Afr Med J* 2014; **104**: 307-309 [PMID: 25118561 DOI: 10.7196/samj.7299]

60 **Kafeero HM**, Ndagire D, Ocama P, Walusansa A, Sendagire H. Sero-prevalence of human immunodeficiency virus-hepatitis B virus (HIV-HBV) co-infection among pregnant women attending antenatal care (ANC) in sub-Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-analysis. *Virol J* 2020; **17**: 170 [PMID: 33160386 DOI: 10.1186/s12985-020-01443-6]

61 **UNAIDS.** UNAIDS data 2020. 2nd edition, February 2021. Available from: https://www.unaids.org/sites/default/files/media\_asset/2020\_aids-data-book\_en.pdf

62 **Slogrove AL**, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global population of children who are HIV-exposed and uninfected, 2000-18: a modelling study. *Lancet Glob Health* 2020; **8**: e67-e75 [PMID: 31791800 DOI: 10.1016/S2214-109X(19)30448-6]

63 **Jones CE**, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. *JAMA* 2011; **305**: 576-584 [PMID: 21304083 DOI: 10.1001/jama.2011.100]

64 **Njom Nlend AE**, Nguwoh PS, Ngounouh CT, Tchidjou HK, Pieme CA, Otélé JM, Penlap V, Colizzi V, Moyou RS, Fokam J. HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings? *PLoS One* 2016; **11**: e0161714 [PMID: 27656883 DOI: 10.1371/journal.pone.0161714]

65 **Baruti K**, Lentz K, Anderson M, Ajibola G, Phinius BB, Choga WT, Mbangiwa T, Powis KM, Sebunya T, Blackard JT, Lockman S, Moyo S, Shapiro R, Gaseitsiwe S. Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana. *PLoS One* 2020; **15**: e0237252 [PMID: 32764801 DOI: 10.1371/journal.pone.0237252]

66 **Tamandjou Tchuem C**, Cotton MF, Nel E, Tedder R, Preiser W, Violari A, Bobat R, Hovind L, Aaron L, Montepiedra G, Mitchell C, Andersson MI. Viral hepatitis B and C in HIV-exposed South African infants. *BMC Pediatr* 2020; **20**: 563 [PMID: 33357228 DOI: 10.1186/s12887-020-02479-x]

67 **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

68 **Okeke E**, Davwar PM, Roberts L, Sartorius K, Spearman W, Malu A, Duguru M. Epidemiology of Liver Cancer in Africa: Current and Future Trends. *Semin Liver Dis* 2020; **40**: 111-123 [PMID: 31726474 DOI: 10.1055/s-0039-3399566]

69 **Howell J,** Ladepa NG, Lemoinea M, Thursza MR., Taylor-Robinsona SD. Hepatitis B in sub-Saharan Africa. *South Sudan Med J* 2014; **7**: 59-61

70 **Shimakawa Y**, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, Jatta A, Jeng-Barry A, Wegmuller R, Moore SE, Baldeh I, Taal M, D'Alessandro U, Whittle H, Njie R, Thursz M, Mendy M. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. *Gut* 2016; **65**: 2007-2016 [PMID: 26185161 DOI: 10.1136/gutjnl-2015-309892]

71 **Yang JD**, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Afihene MY, Duduyemi BM, Ayawin JP, Gyedu A, Lohouès-Kouacou MJ, Ndam AW, Moustafa EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE, Anthony R, Palmer D, Nyanga AF, Malu AO, Obekpa S, Abdo AE, Siddig AI, Mudawi HM, Okonkwo U, Kooffreh-Ada M, Awuku YA, Nartey YA, Abbew ET, Awuku NA, Otegbayo JA, Akande KO, Desalegn HM, Omonisi AE, Ajayi AO, Okeke EN, Duguru MJ, Davwar PM, Okorie MC, Mustapha S, Debes JD, Ocama P, Lesi OA, Odeghe E, Bello R, Onyekwere C, Ekere F, Igetei R, Mah'moud MA, Addissie B, Ali HM, Gores GJ, Topazian MD, Roberts LR; Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. *Lancet Gastroenterol Hepatol* 2017; **2**: 103-111 [PMID: 28403980 DOI: 10.1016/S2468-1253(16)30161-3]

72 **Moore SW**, Millar AJ, Hadley GP, Ionescu G, Kruger M, Poole J, Stones D, Wainwright L, Chitnis M, Wessels G. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. *Cancer* 2004; **101**: 642-649 [PMID: 15274079 DOI: 10.1002/cncr.20398]

73 **Seleye-Fubara D**, Jebbin NJ. Hepatocellular carcinoma in Port Harcourt, Nigeria: clinicopathologic study of 75 cases. *Ann Afr Med* 2007; **6**: 54-57 [PMID: 18240703 DOI: 10.4103/1596-3519.55716]

74 **Carreira H**, Lorenzoni C, Carrilho C, Ferro J, Sultane T, Garcia C, Amod F, Augusto O, Silva-Matos C, La Vecchia C, Lunet N. Spectrum of pediatric cancers in Mozambique: an analysis of hospital and population-based data. *Pediatr Hematol Oncol* 2014; **31**: 498-508 [PMID: 24852201 DOI: 10.3109/08880018.2014.909547]

75 **Stefan C**, Bray F, Ferlay J, Liu B, Maxwell Parkin D. Cancer of childhood in sub-Saharan Africa. *Ecancermedicalscience* 2017; **11**: 755 [PMID: 28900468 DOI: 10.3332/ecancer.2017.755]

76 **Bray F**, Møller B. Predicting the future burden of cancer. *Nat Rev Cancer* 2006; **6**: 63-74 [PMID: 16372017 DOI: 10.1038/nrc1781]

77 **Ferlay J,** Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Tomorrow. Lyon: International Agency for Research on Cancer, 2020

78 **Ferlay J,** Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2020

79 **Sartorius K**, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. *Cancer Epidemiol* 2015; **39**: 284-290 [PMID: 25922178 DOI: 10.1016/j.canep.2015.04.006]

80 **Wang CC**, Tsai MC, Peng CM, Lee HL, Chen HY, Yang TW, Sung WW, Lin CC. Favorable liver cancer mortality-to-incidence ratios of countries with high health expenditure. *Eur J Gastroenterol Hepatol* 2017; **29**: 1397-1401 [PMID: 29023320 DOI: 10.1097/MEG.0000000000000969]

81 **Spearman CW**, Sonderup MW. Health disparities in liver disease in sub-Saharan Africa. *Liver Int* 2015; **35**: 2063-2071 [PMID: 26053588 DOI: 10.1111/liv.12884]

82 **Mak D**, Sengayi M, Chen WC, Babb de Villiers C, Singh E, Kramvis A. Liver cancer mortality trends in South Africa: 1999-2015. *BMC Cancer* 2018; **18**: 798 [PMID: 30086727 DOI: 10.1186/s12885-018-4695-9]

83 **Kirk GD**, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, Hainaut P, Hall AJ, Whittle H, Montesano R. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. *Hepatology* 2004; **39**: 211-219 [PMID: 14752840 DOI: 10.1002/hep.20027]

84 **Otedo A**, Simbiri KO, Were V, Ongati O, Estambale BA. Risk factors for liver Cancer in HIV endemic areas of Western Kenya. *Infect Agent Cancer* 2018; **13**: 41 [PMID: 30607173 DOI: 10.1186/s13027-018-0214-5]

85 **Kirk GD**, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, Hainaut P, Montesano R. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. *Oncogene* 2005; **24**: 5858-5867 [PMID: 16007211 DOI: 10.1038/sj.onc.1208732]

86 **Kew MC**. Aflatoxins as a cause of hepatocellular carcinoma. *J Gastrointestin Liver Dis* 2013; **22**: 305-310 [PMID: 24078988]

87 **Kew MC**. Hepatitis C virus-induced hepatocellular carcinoma in sub-Saharan Africa. *J Afr Cancer* 2013; **5**: 169-174 [DOI: 10.1007/s12558-013-0275-8]

88 **Amponsah-Dacosta E**, Tamandjou Tchuem C, Anderson M. Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome. *World J Virol* 2020; **9**: 54-66 [PMID: 33362998 DOI: 10.5501/wjv.v9.i5.54]

89 **Yu MC**, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S72-S78 [PMID: 15508106 DOI: 10.1016/j.gastro.2004.09.018]

90 **Baecker A**, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. *Eur J Cancer Prev* 2018; **27**: 205-212 [PMID: 29489473 DOI: 10.1097/CEJ.0000000000000428]

91 **Petruzziello A**. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. *Open Virol J* 2018; **12**: 26-32 [PMID: 29541276 DOI: 10.2174/1874357901812010026]

92 **Levrero M**, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. *J Hepatol* 2016; **64**: S84-S101 [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021]

93 **Torresi J**, Tran BM, Christiansen D, Earnest-Silveira L, Schwab RHM, Vincan E. HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models. *BMC Cancer* 2019; **19**: 707 [PMID: 31319796 DOI: 10.1186/s12885-019-5916-6]

94 **Atsama Amougou M**, Marchio A, Bivigou-Mboumba B, Noah Noah D, Banai R, Atangana PJA, Fewou Moundipa P, Pineau P, Njouom R. Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. *J Viral Hepat* 2019; **26**: 1086-1093 [PMID: 31106515 DOI: 10.1111/jvh.13131]

95 **Mak D**, Babb de Villiers C, Chasela C, Urban MI, Kramvis A. Analysis of risk factors associated with hepatocellular carcinoma in black South Africans: 2000-2012. *PLoS One* 2018; **13**: e0196057 [PMID: 29718992 DOI: 10.1371/journal.pone.0196057]

96 **Mendy ME**, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. *J Viral Hepat* 2010; **17**: 115-122 [PMID: 19874478 DOI: 10.1111/j.1365-2893.2009.01168.x]

97 **Polaris Observatory Collaborators**. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; **3**: 383-403 [PMID: 29599078 DOI: 10.1016/S2468-1253(18)30056-6]

98 **Wilson P**, Parr JB, Jhaveri R, Meshnick SR. Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. *J Infect Dis* 2018; **217**: 1180-1183 [PMID: 29351639 DOI: 10.1093/infdis/jiy028]

99 **Sonderup MW**, Dusheiko G, Desalegn H, Lemoine M, Tzeuton C, Taylor-Robinson SD, Spearman CW. Hepatitis B in sub-Saharan Africa-How many patients need therapy? *J Viral Hepat* 2020; **27**: 560-567 [PMID: 31800145 DOI: 10.1111/jvh.13247]

100 **Béguelin C**, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 537-546 [PMID: 29737218 DOI: 10.1080/17474124.2018.1474097]

101 **Desalegn H**, Aberra H, Berhe N, Gundersen SG, Johannessen A. Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa? *Liver Int* 2017; **37**: 1461-1467 [PMID: 28222249 DOI: 10.1111/liv.13393]

102 **Lemoine M**, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. *J Hepatol* 2017; **66**: 645-654 [PMID: 27771453 DOI: 10.1016/j.jhep.2016.10.013]

103 **Boye S**, Shimakawa Y, Vray M, Giles-Vernick T. Limited Awareness of Hepatitis B but Widespread Recognition of Its Sequelae in Rural Senegal: A Qualitative Study. *Am J Trop Med Hyg* 2020; **102**: 637-643 [PMID: 31971148 DOI: 10.4269/ajtmh.19-0477]

104 **Adjei CA**, Stutterheim SE, Naab F, Ruiter RAC. Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers. *PLoS One* 2019; **14**: e0225830 [PMID: 31794577 DOI: 10.1371/journal.pone.0225830]

105 **World Health Organization Regional Office for Africa**. Sixty-fourth session of the WHO Regional Committee for Africa. 2014. Available from: https://www.afro.who.int/about-us/governance/sessions/sixty-fourth-session-who-regional-committee-africa

106 **World Health Organization Regional Office for Africa**. Regional strategic plan for immunization 2014 – 2020. 2015. Available from: https://www.afro.who.int/sites/default/files/2017-06/oms-ivb-rvap-afro-en-20150408\_final\_sent140317.pdf

107 **Andersson MI**, Rajbhandari R, Kew MC, Vento S, Preiser W, Hoepelman AI, Theron G, Cotton M, Cohn J, Glebe D, Lesi O, Thursz M, Peters M, Chung R, Wiysonge C. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. *Lancet Glob Health* 2015; **3**: e358-e359 [PMID: 26087980 DOI: 10.1016/S2214-109X(15)00056-X]

108 **Stockdale AJ**, Geretti AM. Chronic hepatitis B infection in sub-Saharan Africa: a grave challenge and a great hope. *Trans R Soc Trop Med Hyg* 2015; **109**: 421-422 [PMID: 26065660 DOI: 10.1093/trstmh/trv044]

109 **Jia L**, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. *Pharmacol Res* 2020; **159**: 104992 [PMID: 32505833 DOI: 10.1016/j.phrs.2020.104992]

110 **Yang JD**, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. *BMJ* 2020; **371**: m3544 [PMID: 33106289 DOI: 10.1136/bmj.m3544]

**Footnotes**

**Conflict-of-interest statement:** The author has no conflict of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** World Society for Virology; Health Systems Global, No. 56106488.

**Peer-review started:** February 28, 2021

**First decision:** May 1, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** South Africa

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Peng S **S-Editor:** Wang JL **L-Editor:** Webster JR **P-Editor:**

**Figure Legends**



**Figure 1 Projected increase in estimated number of cases and deaths due to cancers of the liver and intrahepatic bile ducts within sub-Saharan Africa from 2020 to 2040[67,76,77].** GLOBOCAN 2020 (https://gco.iarc.fr/). A: Estimated number of cases from 2020 to 2040, both sexes, age (0-85+); B: Estimated number of deaths from 2020 to 2040, both sexes, age (0-85+).



**Figure 2 Estimated age-standardized liver cancer incidence and mortality rates per 100000 persons per year shown worldwide in 2020[2,67,78].** GLOBOCAN 2020 (https://gco.iarc.fr/). WHO: World Health Organization; ASR: Liver cancer age standardized incidence rate.



**Figure 3 Estimated age-standardized liver cancer incidence rates per 100000 persons per year in males in Africa (2020)[2,67,78].** GLOBOCAN 2020 (https://gco.iarc.fr/). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization/International Agency for Research on Cancer concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted or dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

****

**Figure 4 Estimated age-standardized liver cancer mortality rates per 100000 persons per year in males in Africa (2020)[2,67,78].** GLOBOCAN 2020 (https://gco.iarc.fr/). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization/International Agency for Research on Cancer concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted or dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

**Table 1 Prevalence of hepatitis B surface antigen among pre- *vs* post-hepatitis B vaccine introduction populations in some sub-Saharan African countries**

|  |  |  |
| --- | --- | --- |
| Country | Year of hepatitis B vaccine introduction1 | Prevalence of HBsAg (%) |
| **Pre-vaccine introduction** | **Post-vaccine introduction** |
| **< 15-yr-olds**  | **≥ 15-yr-olds** |
| Burundi | 2004 | 11.0[15] | 2.6[16] | 1.0-4.6[17] |
| Democratic Republic of Congo | 2007 | > 20.7[18] | 2.2[19] | 3.7[19] |
| Ethiopia | 2007 | 11.0[20] | 4.4[21] | 7.4[22] |
| Gambia | 1990 | 20.0[23] | 0.4[24] | 10.0[25] |
| Kenya | 2002 | 11.4[26] | 0.9[16] | 3.4[27] |
| Mali | 2003 | > 8.7[28] | 4.9[16] | 8.5[16] |
| Mozambique | 2001 | 14.6[29] | 3.7[16] | 4.5[30] |
| Namibia | 2009 | 14.0[31] | 2.7[32] | 1.8[33] |
| Nigeria | 2004 | 13.3[34] | 11.5[35] | 8.2[36] |
| Rwanda | 2002 | Approximately 5.0[37] | 1.7[16] | 2.2[38] |
| Senegal | 2004 | 11.8[39] | 1.6[40] | > 11.0[41] |
| South Africa | 1995 | 9.6[15] | 0.4[42] | 4.0[43] |
| Uganda | 2002 | 10.3[44] | 0.6[45] | 4.1[45] |
| Zimbabwe | 2000 | 15.4[46] | 4.4[16] | 3.3[47] |

1The year the hepatitis B vaccine was introduced into national Expanded Programme on Immunization. HBsAg: Hepatitis B surface antigen.